(Q38056076)

27 August 2017

title

Cabozantinib for the treatment of advanced medullary thyroid cancer (English)

1 reference

27 August 2017

1 reference

ChEBI release 2020-05-28

3

Ezra E W Cohen

1 reference

27 August 2017

Madhavi Nagilla

1

1 reference

27 August 2017

Rebecca L Brown

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

25 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

29

1 reference

27 August 2017

issue

11

1 reference

27 August 2017

page(s)

925-934

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-012-0060-6

27 August 2017

exact match

0 references

cites work

New therapeutic approaches to treat medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

The role of external beam radiation and targeted therapy in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Adjuvant external beam radiation for medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Imatinib induces hypothyroidism in patients receiving levothyroxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Serum vascular endothelial growth factor levels in patients with medullary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

MET signaling: novel targeted inhibition and its clinical development in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0060-6

10.1007/S12325-012-0060-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1023864940

0 references

1 reference